CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03, FiscalAI reports.
CNS Pharmaceuticals Stock Performance
Shares of CNSP stock opened at $2.99 on Monday. The firm has a market cap of $4.37 million, a P/E ratio of -0.13 and a beta of 3.21. CNS Pharmaceuticals has a fifty-two week low of $1.90 and a fifty-two week high of $10.54. The business’s 50 day moving average price is $4.96 and its 200-day moving average price is $4.47.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has an average rating of “Sell”.
About CNS Pharmaceuticals
CNS Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancers of the brain and central nervous system. Its research has centered on investigational therapies intended to address the challenges of treating tumors that affect these areas. The company’s lead candidate has been berubicin, an experimental anthracycline designed to cross the blood-brain barrier. CNS Pharmaceuticals has evaluated berubicin for glioblastoma, an aggressive form of brain cancer. The drug remains investigational and is not an approved treatment.
Featured Stories
- Five stocks we like better than CNS Pharmaceuticals
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
